CymaBay Therapeutics Inc CBAY
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover CBAY, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Gilead Sciences Announces Completion of Acquisition of CymaBay
-
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
-
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE
-
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 111.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 101
- Website
- https://www.cymabay.com
Comparables
Valuation
|
Metric
|
CBAY
|
DYN
|
MORF
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 12.65 | 4.85 | 2.17 |
Price/Sales | 111.01 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CBAY
DYN
MORF
Financial Strength
|
Metric
|
CBAY
|
DYN
|
MORF
|
|---|---|---|---|
Quick Ratio | 10.70 | 2.41 | 28.43 |
Current Ratio | 10.96 | 2.53 | 28.94 |
Interest Coverage | −5.27 | — | — |
Quick Ratio
CBAY
DYN
MORF
Profitability
|
Metric
|
CBAY
|
DYN
|
MORF
|
|---|---|---|---|
Return on Assets (Normalized) | −30.06% | −77.53% | −18.85% |
Return on Equity (Normalized) | −51.97% | −94.92% | −19.43% |
Return on Invested Capital (Normalized) | −30.87% | −88.19% | −23.26% |
Return on Assets
CBAY
DYN
MORF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cwtydknl | Fczm | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pjgpqyd | Dkyjyk | $110.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cgtflvkx | Yptskr | $107.6 Bil | |
MRNA
| Moderna Inc | Vfckqylz | Tcgf | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Hhshjzsh | Cld | $22.1 Bil | |
ARGX
| argenx SE ADR | Hzksxnncz | Jnlmb | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bwbjmqq | Vznppt | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Htrcbmhvx | Snzmtq | $15.3 Bil | |
INCY
| Incyte Corp | Zlxzhmwf | Gmxgqfl | $13.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qnlmrctrv | Ltcmdqn | $12.7 Bil |